- Amylin Adventure – Vindico Medical Education
- YouTube – Amylin Adventure: Biology and Modes of Action
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
- Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
- What is the pipeline for future medications for obesity?
- Central nervous system pathways targeted by amylin in the regulation of food intake
- SURMOUNT-1: 3-Year Safety on Tirzepatide for Obesity Treatment and Diabetes Prevention
- SURMOUNT-1 Substudy: Body Composition Changes During Weight Reduction With Tirzepatide in Adults With Obesity or Overweight
- First-in-class GLP-1 and Amylin Receptor Agonist, Amycretin: Phase 1 Trial
- Subcutaneous Amycretin: A Phase 1b/2a Randomised Controlled Study
- REDEFINE-1 Phase 3a: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- REDEFINE-2 Phase 3a: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- Evolving Approaches for Pharmacological Therapy of Obesity
- New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial
- Effects of Retatrutide on Body Composition on People With Type 2 Diabetes: A Substudy of the Phase 2 Trial
- ACHIEVE-1 Phase 3: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
- SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
- SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
- Obesity and CVD: A Scientific Statement from the American Heart Association
- Lancet Diabetes and Endocrinology Global Commission: Definition and Diagnostic Criteria of Clinical Obesity
- Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
- AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
- Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
- Patient Resource: Your Obesity Care Team
- Internet Tracking Tools for the Bariatric Patient
- CDC: Healthy Weight, Nutrition, and Physical Activity—Planning Meals
- Who's Who on the Obesity Care Team – Patient Education
- 2023 Consensus Statement on Obesity
- Curated Resources for the Management of Obesity in the Primary Care Setting
- Guide for the Management of Obesity in the Primary Care Setting
- Prescription Medications to Treat Overweight and Obesity
- Bariatric Surgery: Patient Materials
- STOP Obesity Alliance – WHY WEIGHT? A Guide to Discussing Obesity & Health with Your Patients
- American Board of Obesity Medicine (ABOM)
- How To Use Fruits and Vegetables – Patient Handout
- Rethink Your Drink – Patient Materials
- Childhood Obesity Facts
About
Contact Us
For General inquiries, contact:
[email protected]
For Technical questions, contact:
[email protected]
For CME questions, contact:
[email protected]
Vindico Medical Education
6900 Grove Road
Building 100
Thorofare, NJ 08086-9447 USA
888-960-0256; 856-994-9400
FAX: 856-384-6680
Vindico Medical Education, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team through November 30, 2026.
Legal
© Vindico Medical Education All Rights Reserved.